Aims: A bidirectional cohort study investigates whether pre-travel vaccination with whole cell/recombinant B subunit inactivated, killed oral cholera vaccine reduces the incidence of diarrhoea in young adult travellers to high-risk areas.
Scope: Risk of travellers' diarrhoea was assessed according to destination and reason for travel in high-risk travellers of a travel clinic in Barcelona, Spain. Those at high-risk between January and December 2005 were advised on water/food safety and hygiene. High-risk travellers between January and December 2006 were additionally vaccinated with WC/rBS oral cholera vaccine. Data regarding diarrhoea were gathered by structured telephone interview or e-mailed questionnaire following the travellers' return. The incidence of diarrhoea in the group vaccinated with WC/rBS oral cholera vaccine (n=321) was 17.4%, compared with 39.7% in the non-vaccinated group (n=337) (adjusted risk ratio 0.40). The first episode was significantly shorter in the vaccinated group (mean 2.3 days) than in the non-vaccinated group (mean 3.8 days) (p<0.001).
Conclusions: The protective effect of the WC/rBS oral cholera vaccine was 57% in the young, high-risk travellers. Vaccination with the WC/rBS oral cholera vaccine as well as food safety and hygiene advice could offer effective means of reducing the risk of diarrhoea while abroad.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2009.04.025 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The 30-year evolution of oral cholera vaccines: A case study of a collaborative network alternative innovation model.
PLOS Glob Public Health
January 2025
Global Health Centre, Geneva Graduate Institute, Genève, Switzerland.
Cholera outbreaks have been rapidly increasing around the world. While long-term cholera prevention and control measures rely on improvements in water, sanitation, and hygiene, oral cholera vaccines (OCVs) are used for prevention and control in the short-to-medium term. OCVs lack the market incentives available in other more profitable disease areas.
View Article and Find Full Text PDFOn the ability to extract MLVA profiles of Vibrio cholerae isolates from WGS data generated with Oxford Nanopore Technologies.
BMC Res Notes
January 2025
Center for Applied Molecular Technologies (CTMA), Institute of Clinical and Experimental Research (IREC), Université catholique de Louvain (UCLouvain), Brussels, Belgium.
Objective: Multiple-Locus Variable Number of Tandem Repeats (VNTR) Analysis (MLVA) is widely used to subtype pathogens causing foodborne and waterborne disease outbreaks. The MLVAType shiny application was previously designed to extract MLVA profiles of Vibrio cholerae isolates from whole-genome sequencing (WGS) data, and provide backward compatibility with traditional MLVA typing methods. The previous development and validation work was conducted using short (pair-end 300 and 150 nt long) reads from Illumina MiSeq and Hiseq sequencing.
View Article and Find Full Text PDFRisk Communication and Community Engagement (RCCE) implementations to control cholera outbreak in Oromia region, Ethiopia.
Trop Med Health
January 2025
School of Medical Laboratory Sciences, Institute of Health, Jimma University, Jimma, Ethiopia.
Background: Oromia regional state experiencing cholera outbreaks in a protracted pattern despite various interventions at local and regional levels. This study aimed to examine the implementation of Risk Communication and Community Engagement (RCCE) activities for cholera outbreak control in the region.
Methods: We conducted a quantitative and qualitative mixed-method study.
Geographic disparities impacting oral vaccine performance: Observations and future directions.
Clin Exp Immunol
January 2025
Bill & Melinda Gates Foundation, Seattle, WA, USA.
Oral vaccines have several advantages compared with parenteral administration: they can be relatively cheap to produce in high quantities, easier to administer, and induce intestinal mucosal immunity that can protect against infection. These characteristics have led to successful use of oral vaccines against rotavirus, polio, and cholera. Unfortunately, oral vaccines for all three diseases have demonstrated lower performance in the highest-burden settings where they are most needed.
View Article and Find Full Text PDFProtection by natural cholera against later episodes of cholera over 10 years of follow-up in Matlab, Bangladesh: a retrospective cohort study.
Lancet Microbe
January 2025
International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh; International Vaccine Institute, Seoul, South Korea; UCLA Fielding School of Public Health, Los Angeles, CA, USA; Vaccine Innovation Center, Korea University School of Medicine, Seoul, South Korea. Electronic address:
Background: Patients with cholera have been shown to be protected against subsequent cholera for 3 years after their initial episode. We aimed to assess protection at 10 years of follow-up.
Methods: In this retrospective cohort study, cohorts of patients treated for cholera (index patients) and contemporaneously selected age-matched individuals without cholera (controls), randomly selected from the population of Matlab, Bangladesh, were assembled between 1990 and 2009 and followed for up to 10 years.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!